The ACTN4 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the HT29 human colon adenocarcinoma cell line, engineered to disrupt the ACTN4 gene and eliminate alpha-actinin-4 protein expression. This loss-of-function model provides a powerful tool for investigating the roles of ACTN4 in cytoskeletal dynamics, cell adhesion, migration, invasion, and signal transduction within an intestinal epithelial context.
The HT29 host line was originally isolated from a primary colorectal adenocarcinoma of a 44-year-old Caucasian female. These cells exhibit epithelial morphology and can differentiate into enterocyte-like cells, making them a well-established model for studying colorectal adenocarcinoma biology, intestinal epithelial barrier function, and drug absorption mechanisms.
Alpha-actinin-4, encoded by ACTN4, is a critical actin-bundling protein that crosslinks F-actin filaments and anchors them to focal adhesion complexes, where it interacts with vinculin, talin, paxillin, integrin-??1, and focal adhesion kinase (FAK). ACTN4 functions downstream of PI3K/Akt signaling and is transcriptionally regulated by the ??-catenin/TCF complex in the Wnt pathway, while also responding to TGF-??/SMAD and EGF receptor pathways. Through these interactions, ACTN4 modulates cytoskeletal organization and cellular mechanotransduction, influencing cell migration, invasion, and epithelial-mesenchymal transition (EMT) by regulating genes such as SNAI1 and CDH1. The protein further interacts with calmodulin, 14-3-3??, and Rho GTPases, integrating multiple upstream signals to control adhesion dynamics and cellular morphology.
Disruption of ACTN4 in HT29 cells perturbs focal adhesion turnover and actin stress fiber formation, leading to impaired migration and invasion??phenotypes central to colorectal cancer metastasis. This model thus holds particular significance for dissecting the molecular mechanisms underlying EMT and tumor cell dissemination in colon adenocarcinoma, as well as for exploring the crosstalk between Wnt/??-catenin and integrin signaling pathways.
Researchers can utilize this polyclonal knockout pool for a wide array of assays: Western blotting to confirm ACTN4 loss and assess EMT marker expression (E-cadherin, vimentin), immunofluorescence to visualize actin architecture and focal adhesion integrity, wound-healing and transwell assays to quantify migratory and invasive capacity, and phospho-signaling arrays to monitor Akt or FAK activation. The cells are also suitable for RNA-seq-based transcriptomic profiling, co-immunoprecipitation studies of protein complexes, and drug screening campaigns aimed at identifying anti-metastatic compounds. For additional information, technical support, or validation data, please contact Ascent Research.
